BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25356874)

  • 1. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
    Rocha CR; Garcia CC; Vieira DB; Quinet A; de Andrade-Lima LC; Munford V; Belizário JE; Menck CF
    Cell Death Dis; 2014 Oct; 5(10):e1505. PubMed ID: 25356874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
    Zhu Z; Du S; Du Y; Ren J; Ying G; Yan Z
    J Neurochem; 2018 Jan; 144(1):93-104. PubMed ID: 29105080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
    Hayashi T; Adachi K; Ohba S; Hirose Y
    J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
    Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S; Hirose Y; Kawase T; Sano H
    J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
    Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
    Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
    Chio CC; Tai YT; Mohanraj M; Liu SH; Yang ST; Chen RM
    Phytomedicine; 2018 Oct; 49():41-51. PubMed ID: 30217261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
    J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.